Episode Details

The Pharma Closeout's comprehensive recap of EHA 2026(Stockholm, June 11-14). HEADLINE: J&J's MonumenTAL-3 (talquetamab +daratumumab) in earlier-line R/R myeloma — PFS HR 0.28/0.33, complete-response 71% vs 34.5%, NEJM-published; ~73% dysgeusia the caveat.

AML: the menin inhibitor frontline class war — ziftomenib KOMET-007 (CRc 96% NPM1m / 90%KMT2Ar) vs revumenib (frontline CRc 97%; SAVE ORR 88%) — and the gilteritinib-vs-midostaurin FLT3 survival miss (HR 1.02).

CLL: BRUIN CLL-322 — pirtobrutinib + venetoclax-rituximab, PFS HR 0.55, first Phase 3 to beat a venetoclax control.

LYMPHOMA: frontMIND (tafasitamab+len+R-CHOP, 1L DLBCL, PFS HR 0.75) and EPCORE DLBCL-1 (epcoritamab wins PFS, misses OS). MYELOFIBROSIS: SENTRY (selinexor+rux, SVR35 49.8% vs 28%, symptom co-primary missed). BENIGN

HEME: warm AIHA gets two drugs (sovleplenib, nipocalimab) in a disease with no approved therapy; CASGEVY first pediatric gene-editing data. Lightning round, discipline corner (why three 'EHA' myeloma headlines were actually ASCO), and what to watch. Three throughlines: immunotherapy moving earlier andoff-the-shelf, a frontline standard-of-care reset, and the survival misses that set the discipline. Stock reactions qualitative only.

pharma, pharmaceutical, hematology, blood cancer, clinicaltrials, biotech, EHA 2026, pharma podcast, The Pharma Closeout